We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PJT:NYSEPJT Partners Inc. Analysis

Data as of 2026-06-17 - not real-time

$159.19

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

PJT is trading just above its 20‑day SMA and comfortably below its 200‑day SMA, indicating a neutral price stance with limited upside from a technical perspective. The RSI sits in the mid‑50s, suggesting neither over‑bought nor over‑sold conditions, while the MACD histogram is negative and the signal line is bearish, pointing to short‑term momentum weakness. Volume has been trending down, and the stock is hovering near the identified resistance level, which may cap near‑term gains. However, the company’s revenue growth of roughly 29% and gross margin above 95% underscore a robust business model, and a return on equity near 37% signals high profitability relative to peers. The forward PE of 18.6 is well below the current trailing PE of 22.7 and the industry average, hinting at improving valuation as earnings are expected to rise. A discounted cash‑flow analysis places fair value near $410, implying a potential upside of over 150% versus the current price, while the upside/downside metric still shows modest upside of around 6%. The market’s “Extreme Greed” sentiment (fear/greed index >90) may be inflating short‑term demand, but the stock’s beta close to 1 and 30‑day volatility above 27% suggest heightened price swings. The dividend yield of 0.63% with a payout ratio under 15% appears sustainable given strong cash generation. Overall, the blend of solid fundamentals, attractive long‑term valuation, and cautious technical signals supports a nuanced outlook.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD histogram and decreasing volume
  • Price near resistance level limiting upside
  • Neutral RSI indicating no strong directional bias

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong revenue growth and high gross margin
  • DCF fair value indicating substantial upside
  • Improving forward PE relative to industry

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • High ROE and durable profitability
  • Sustainable dividend with low payout ratio
  • Strategic advisory niche providing resilient cash flow

Key Metrics & Analysis

Financial Health

Revenue Growth28.90%
Profit Margin10.33%
P/E Ratio22.7
ROE37.04%
ROA21.94%
Debt/Equity45.34
P/B Ratio15.1
Op. Cash Flow$666.5M
Industry P/E17.1

Technical Analysis

TrendNeutral
RSI55.3
Support$150.69
Resistance$163.65
MA 20$156.03
MA 50$155.21
MA 200$163.65
MACDBearish
VolumeDecreasing
Fear & Greed Index92.13

Valuation

Fair Value$410.32
Target Price$169.80
Upside/Downside6.66%
GradeUndervalued
TypeGrowth
Dividend Yield0.63%

Risk Assessment

Beta0.98
Volatility27.30%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.